Cost and Access for Non-Diabetic GLP-1 Users PlexusDx eliminates insurance barriers by offering direct-to-patient compounded semaglutide, tirzepatide, and combination GLP-Squared formulations without membership fees or insurance requirements
Seven additional Phase 3 trials are expected to complete throughout 2026
An FDA-approved drug is reviewed as a specific product with defined manufacturing controls, labeling, and evidence for approved uses
Without timestamped records, it becomes impossible to separate medication effects from lifestyle changes or to distinguish between symptoms that will resolve and those that signal a need for intervention
Phase 2 trials in patients with pressure ulcers, venous stasis ulcers and epidermolysis bullosa wounds, for instance, found that thymosin beta-4 accelerated wound healing by roughly a month in those who healed, indicating effects on tissue repair and inflammatory modulation in clinical contexts